GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Valuation Rank

Sanofi (Sanofi) Valuation Rank


View and export this data going back to 2009. Start your Free Trial

What is Sanofi Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sanofi Valuation Rank Related Terms

Thank you for viewing the detailed overview of Sanofi's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Valuation Rank
Comparable Companies
XPAR:VIRP LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 BIIB XTER:BAYN TSE:4578 SHSE:600436
Traded in Other Exchanges
SNY:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria
Address
46, avenue de la Grande Armée, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.